The Boston Memory Center, the Nation's Leading Independent Clinical Evaluator of Memory Loss and Related Cognitive Disorders, Announces Successful Results of its Just Released Double Blind, Randomized, Placebo-Based Human Trial
HOBOKEN, NJ / ACCESSWIRE / December 17, 2014 / Optigenex Inc. (OTC Pink: OPGX) (PINKSHEETS: OPGX), announced today results of an Onnit Labs sponsored clinical trial validating the effectiveness of Onnit's highly popular, nutrient-based supplement called Alpha BRAIN(TM) with ac-11(R) in enhancing verbal memory, mental focus and other vital cognitive functions. The work, which was conducted by the world-famous Boston Memory Center, involved 63 volunteer patients participating in a randomized, double blind, placebo controlled clinical trial using AlphaBRAIN(TM) orally administered. As reported by the Center, the clinical trial fully confirmed the results of an earlier "proof of concept" pilot study that was conducted by the Center earlier this year.
Daniel Zwiren, CEO of Optigenex, said, "It is significant that this clinical trial was conducted under rigorous scientific standards that we seldom, if ever, see elsewhere in the dietary supplement industry. Onnit was confident enough in Alpha BRAIN(TM) with ac-11(R) to subject it to the kind of stepped-up scrutiny for which the independent, physician and Ph.D.- led Boston Memory Center is renowned. Onnit's reward for taking the road less traveled lies in the fact that AlphaBRAIN(TM) as a nootropic now exists in a class by itself, separate from all other so-called memory and cognitive supplements on the market, few if any of which show data of any kind, much less verified clinical trials, to support their claims. It is for this reason, as well as the fact that the maker of AlphaBRAIN(TM) is a world class partner in every conceivable respect, that Optigenex is proud to say that Onnit is and will remain our exclusive global licensee for ac-11(R) in nootropic support and other related health applications."
Aubrey Marcus, CEO of Onnit Labs, LLC, added, "The convincing data we saw on ac-11(R)'s reparative qualities on the cellular level are what initially influenced our decision a few years back to include this all natural, water soluble extract in the AlphaBRAIN(TM) formula. Because our strategy from the beginning was to identify and incorporate in our products only the most effective and safe compounds and ingredients, we believe the exciting results reported by the Boston Memory Center serve as an exclamation point to validate our original judgments. Accordingly, we continue to be delighted to have ac-11(R) featured exclusively in our proprietary flagship nootropic, Alpha BRAIN(TM)."
To view the results of the study, please visit: https://www.onnit.com/academy/alpha-brain-nootropic-shows-statistical-significance-in-groundbreaking-clinical-trial/.
About Optigenex Inc.:
Optigenex is a formulator, distributor and provider of proprietary next generation, dietary supplements, skin care products and bulk ingredient featuring ac-11(R) as its core platform technology. AC-11(R) (formerly known as C-MED-100(R)) is a patented, bioactive and water soluble rain forest ingredient derived from the medicinal herb Uncaria tomentosa. For more information about Optigenex, please visit: www.optigenex.com.
About Onnit Labs LLC:
Onnit is an Austin, TX based health and wellness company focused on encouraging peak human performance through a combination of unique products and actionable information. With strategies from leading professional athletes and medical practitioners, Onnit is committed to creating naturally derived nutritional supplements and functional foods based upon the latest ingredient science and dietary research. For more information visit: www.Onnit.com or contact [email protected].
*The statements made in this press release have not been evaluated by the Food and Drug Administration (FDA). The products mentioned herein are not intended to treat, diagnose, cure or prevent any disease.
CONTACT:
Daniel Zwiren
Optigenex Inc.
[email protected]
201 653 5195
SOURCE: Optigenex Inc.